User talk:JonMoulton

Morpholino
(Note from Jon Moulton): Due to the extensive use of Morpholino oligos for research that is not part of the search for antisense therapeutics, I recommend against merging Morpholino with Antisense therapy. Due to the structural dissimilarity between Morpholino and Antisense mRNA, I similarly suggest that these headings should not be merged but merely cross-referenced (see the figure in the Morpholino article for a structural comparison). You may remove nospam if you wish to contact me directly: jmoultonnospam@gene-tools.com)
 * Hi John, that was really a note to myself and I would not change anything so big without consulting the talk pages of the relevent pages first. Due to time constraints it will not happen soon but thanks for the input.  With regard to morpholino I see what you mean about the structure, I looked more closely at your figure.  I was thinking of the functional similarity with regard to siRNA, miRNA.  It just seemed that the other two articles did not really add too much more but cross referencing could work well too.  One of the frustrating things with wikipedia is the lack of a good contents or index type system.  I suppose the search can work well but I suppose it would be nice to see concept maps etc. that can link all these ideas together.  I am sure there are many related articles out there that get missed due to a lack of cross referencing.  David D. 22:05, 16 Jun 2005 (UTC)


 * Re: capitalization of "Morpholino": I didn't see it mentioned anywhere in the article that "Morpholino" is a trade name.  Also, the listed references used the term "morpholino" uncapitalized, so I assumed that the capitalization was in error.  If it is in fact a trade name, I would suggest reverting my edit and adding some text to indicate that it is a trade name. Julesd 17:06, 23 May 2008 (UTC)

Image Copyright Problem RE: Image:MorpholinoHeteroduplex.png
Thanks for uploading Image:MorpholinoHeteroduplex.png. The Wikimedia Foundation is very careful about the images included in Wikipedia because of copyright law. We need you to specify two things on the image description page:
 * The copyright holder, and
 * The copyright status

The copyright holder is usually the creator. If the creator was paid to make this image, then their employer may be the copyright holder. If several people collaborated, then there may be more than one copyright holder. If you created this image, then you are the copyright holder.

Because of the large number of images on Wikipedia, we've sorted them using image copyright tags. Just find the right tag corresponding to the copyright status of this image, and paste it onto the image description page like this:.

There are 3 basic ways to licence an image on Wikipedia:
 * An open content licence
 * Public Domain
 * Fair Use


 * The copyright holder gets the best protection of his work by licencing their work under an open content license like the Creative Commons Attribution-ShareAlike licence. If you have the express permission of the copyright holder to licence their work under the above licence, use the image copyright tag: cc-by-sa-2.5.  The GNU Free Documentation License is another choice for licencing one's work.  Again, if you have the express permission of the copyright holder, use the tag: GFDL.


 * The copyright holder can also release his work into the public domain, see here for images released into the public domain.


 * Images from certain sources are automatically release into the Public Domain. This is true for most governments like the federal United States government. (See   here  for images from the government of the USA and here for other governments)  However not all governments release their work into the public domain, such as the UK government (See herefor images from the UK government).  Non-free licence governments are listed here.


 * Also, in some cases, an image is copyrighted but allowed on Wikipedia because of Fair Use. To see if this image qualifies and then how to tag it, see Fair use.

For any other sources of for more information see Image copyright tags. Please remember that if you don't tag your images, they will be deleted.


 * P.S. If you have uploaded other images without including copyright tags, please go back and tag them.  Also, please tag all images that you upload in the future.

If you have any questions, just leave a message on my talk page. Thanks again. --Secretlondon 23:40, 12 September 2005 (UTC)

DNA
You just made a change that says red blood cells have no DNA but cannot divide. Did you really mean that? Did you mean "have no DNA and therefore cannot divide," or "have no DNA but can divide"?P0M 16:43, 20 September 2005 (UTC)

Zebrafish
Good advertising for Morpholinos there! ;-) Rockpocket 02:18, 26 January 2006 (UTC)
 * It is generally considered good practice to avoid extensive editing on subjects that one has a financial interest in. Though of course, that must be balanced against the fact that people with expert knowledge of a subject are often close to it. That said, I have no problem with your input regarding Morpholinos, Jon, and i was only jesting above. Keep up the good work (both here and at GeneTools!) Rockpocket 17:45, 9 February 2006 (UTC)

Source of morpholino
Hi Jon, I see you are a frequent editor of Morpholino, looks good (it is absolutely not my field, but I understand what the company is doing). But I wanted to say something about the links to gene-tools and AVI BioPharma. The reason a page like Wikipedia:Chemical sources exists, is mainly to be able to remove ALL external links to companies sites (more specifically at the moment, I only leave deeplinks to property-pages on company sites, I remove links to homepages). A nice second option that that page give, is that one should be able to find MSDS, spectra, etc. on the same page (if at a certain moment we could make the links from CAS numbers, INCHI etc., but that is another problem).

Having said that, morpholino is not a single compound, it is a group of specifically targeted compounds, it is not associated with one compound-number, for that reason, the ChemicalSources template is indeed not in its place, and indeed should be removed (I have gone through more than 2300 chemical substances, I may have made some mistakes in placing the tag on some of the pages). But, I do believe that links to the companies should be removed from the morpholino site (all of them), the way they are now presented makes them commercial links (I know there are more pages out there that have such links, I probably would make a similar point to those pages when I encounter them). What would be a good way to circumvent things, is write pages about each of the two companies (e.g. like Dow Chemical Company), and put a link to the company homepage (and maybe some similar links) in a section at the bottom.

Hope to see you around. --Dirk Beetstra T C 16:28, 20 July 2006 (UTC)

Hi Dirk,

I set up a Gene Tools page and make the links live to that new page and the existing AVI Biopharma page. That seems a good solution.

Regards, JonMoulton 22:16, 26 July 2006 (UTC)

WOW morpholino references
WOW, i was just thinking of getting around to that, excellent job! It must have taken you ages. David D. (Talk) 18:52, 22 August 2006 (UTC)


 * Hi David D., that was a few hours of learning, cutting and pasting, reformatting and troubleshooting. I like the format, you gave me just enough information to get started.  Thanks! JonMoulton 19:20, 22 August 2006 (UTC)

Cell Penetrating Peptides
Do you really need to cite 5 of your own papers on the CPP page? Considering that DNA delivery is only a small subset of the applications of CPPs, it would be nice to see a more balanced citation list, perhaps of other competitors in the field.

Best, AndrewHires 04:03, 20 March 2007 (UTC)

Hi Andrew,

Those are not my papers. My wife was involved in those publications, sometimes as PI and sometimes only because others used her conjugates. I am familiar with the cell penetrating peptide development effort at AVI BioParma, had those references handy and have read the papers cited there; I've not undertaken a broad search for other papers, nor would I feel comfortable citing other papers which I have not read. You are welcome to edit, of course.

Regards, JonMoulton 14:58, 22 March 2007 (UTC)

Thanks
Hi Jon,

Thanks for fixing my error on the zebrafish page. Seems my old genetics lecturer made a boo-boo, or maybe I just misremembered. –Adrian J. Hunter(talk•contribs) 06:09, 14 April 2007 (UTC)

Image:NonFreeImageRemoved.svg -->
Hello JonMoulton, an automated process has found an image or media file tagged as nonfree media, such as fair use. The image (Image:NonFreeImageRemoved.svg -->) was found at the following location: User talk:JonMoulton. This image or media will be removed per statement number 9 of our non-free content policy. The image or media will be replaced with Image:NonFreeImageRemoved.svg, so your formatting of your userpage should be fine. The image that was replaced will not be automatically deleted, but it could be deleted at a later date. Articles using the same image should not be affected by my edits. I ask you to please not readd the image to your userpage and could consider finding a replacement image licensed under either the Creative Commons or GFDL license or released to the public domain. Thanks for your attention and cooperation. User:Gnome (Bot)-talk 09:31, 17 May 2007 (UTC)

Note to myself
I owe a review on: http://en.wikipedia.org/wiki/Wikipedia:Good_article_candidates

Anticancer trials
I was talking about this and this trial. TimVickers 16:12, 29 May 2007 (UTC)


 * Ah, I hadn't picked up the difference. Perhaps other people might also find this confusing. Could you highlight the distinction between small molecule and oligo morpholinos in the article? TimVickers 16:47, 29 May 2007 (UTC)

Morpholino GA Sweeps: On Hold
I have reviewed Morpholino for GA Sweeps to determine if it still qualifies as a Good Article. In reviewing the article I have found several issues, which I have detailed here. Since you are a main contributor of the article (determined based on this tool), I figured you would be interested in contributing to further improve the article. Please comment there to help the article maintain its GA status. If you have any questions, let me know on my talk page and I'll get back to you as soon as I can. --Happy editing! Nehrams2020 (talk • contrib) 03:57, 7 February 2010 (UTC)

Your submission at Articles for creation
 Eteplirsen, which you submitted to Articles for creation, has been created. The article has been assessed as Start-Class, which is recorded on the article's talk page. You may like to take a look at the grading scheme to see how you can improve the article. You are more than welcome to continue making quality contributions to Wikipedia. Note that because you are a logged-in user, you can create articles yourself, and don't have to post a request. However, you are more than welcome to continue submitting work to Articles for Creation. Thank you for helping improve Wikipedia! Drmies (talk) 15:34, 31 October 2012 (UTC)
 * If you have any questions, you are welcome to ask at the help desk.
 * If you would like to help us improve this process, please consider.

ArbCom elections are now open!
MediaWiki message delivery (talk) 12:57, 23 November 2015 (UTC)

Conflict of interest in Wikipedia
Hi Jon. I spend time working on conflict of interest issues here in Wikipedia, along with my regular editing, which is mostly about health and medicine, including biotech and pharma. I am not an administrator.

I see that you have been a Wikipedia editor for a long time now, focused almost entirely on articles related to your company.

Along with the rest of the publishing industry, the Wikipedia editing community has come to take conflict of interest more seriously as it has evolved, and to formalize how we deal with it.

The way things stand today, your direct editing of these topics is no longer really appropriate. I realize that this may come as somewhat of a surprise to you, and if so I am sorry about that.

Please do have a look at the WP:PAID policy, which has been in place for around 4 years now, and the WP:COI guideline which has also evolved a great deal.

The short story is that we look for disclosure of conflicts of interest at people's user pages (which you have done) as well as locally on talk pages where you want to be active and where you have a conflict of interest.

Along with the disclosure, we look for conflicted editors not to edit directly but rather:
 * a) if you want to create an article relevant to a COI you have, create the article as a draft through the WP:AFC process, disclose your COI on the Talk page with the Template:Connected contributor tag, and then submit the draft article for review (the AfC process sets up a big button for you to click when it is ready) so it can be reviewed before it publishes; and
 * b) And if you want to change content in any existing article on a topic where you have a COI, we ask you to
 * (i) disclose at the Talk page of the article with the Template:Connected contributor tag, putting it at the bottom of the beige box at the top of the page; and
 * (ii) propose content on the Talk page for others to review and implement before it goes live, instead of doing it directly yourself. Just open a new section on the talk page, put the proposed content there formatted just as you would if you were adding it directly to the article, and just below the header (at the top of the editing window) place the  tag to flag it for other editors to review.  In general it should be relatively short so that it is not too much review at once.  Sometimes editors propose complete rewrites, providing a link to their sandbox for example.

Does that make sense? Happy to discuss, if not. Best regards Jytdog (talk) 17:42, 20 September 2018 (UTC)

Disambiguation link notification for September 21
Hi. Thank you for your recent edits. An automated process has detected that when you recently edited Morpholino, you added a link pointing to the disambiguation page PMO ([//dispenser.info.tm/~dispenser/cgi-bin/dablinks.py/Morpholino check to confirm] | [//dispenser.info.tm/~dispenser/cgi-bin/dab_solver.py/Morpholino?client=notify fix with Dab solver]). Such links are usually incorrect, since a disambiguation page is merely a list of unrelated topics with similar titles. (Read the FAQ* Join us at the DPL WikiProject.)

It's OK to remove this message. Also, to stop receiving these messages, follow these opt-out instructions. Thanks, DPL bot (talk) 09:24, 21 September 2018 (UTC)

Test
Testing the connected contributor tag